CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.1%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price was down 1.1% during trading on Tuesday . The company traded as low as $57.14 and last traded at $58.07. Approximately 375,745 shares were traded during trading, a decline of 80% from the average daily volume of 1,842,429 shares. The stock had previously closed at $58.72.

Analyst Ratings Changes

A number of equities research analysts have commented on CRSP shares. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Wells Fargo & Company increased their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd. Mizuho increased their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Royal Bank of Canada increased their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $74.93.

CRISPR Therapeutics Price Performance

The business’s 50-day moving average is $73.51 and its two-hundred day moving average is $63.34.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. During the same quarter last year, the business earned ($1.41) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% on a year-over-year basis. Research analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $60.51, for a total value of $3,025,500.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $11,338,182.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Raju Prasad sold 3,524 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the transaction, the chief financial officer now directly owns 6,476 shares of the company’s stock, valued at $470,740.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 50,000 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at $11,338,182.27. The disclosure for this sale can be found here. Insiders have sold 133,992 shares of company stock worth $9,157,835 over the last ninety days. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jump Financial LLC boosted its position in CRISPR Therapeutics by 194.7% during the third quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock worth $1,512,000 after purchasing an additional 22,006 shares during the period. Baker Chad R bought a new position in CRISPR Therapeutics during the third quarter worth $2,365,000. Capital Advisors Inc. OK boosted its position in CRISPR Therapeutics by 7.4% during the third quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company’s stock worth $10,527,000 after purchasing an additional 15,951 shares during the period. Invesco Ltd. boosted its position in CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,061 shares during the period. Finally, ARK Investment Management LLC boosted its position in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after purchasing an additional 1,372,986 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.